Jaguar Health, Inc.
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
JAGX$0.44+7.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| September 30, · December 31, | ||||
|---|---|---|---|---|
| (In thousands, except share and per share data) · 2025 · 2024 | ||||
| (unaudited) | ||||
| Assets | ||||
| Current assets: | ||||
| Cash | $ | 3,527 | $ | 8,002 |
| Accounts receivable, net | 1,437 | 1,527 | ||
| Other receivable | 67 | 120 | ||
| Inventory | 10,628 | 10,345 | ||
| Prepaid expenses and other current assets | 13,743 | 12,204 | ||
| Total current assets | 29,402 | 32,198 | ||
| Property and equipment, net | 483 | 464 | ||
| Operating lease - right-of-use asset | 1,062 | 936 | ||
| Intangible assets, net | 17,285 | 18,479 | ||
| Other assets | 1,240 | 1,348 | ||
| Total assets | $ | 49,472 | $ | 53,425 |
| Liabilities, Redeemable preferred stock, and Stockholders' equity | ||||
| Current liabilities: | ||||
| Accounts payable | $ | 8,443 | $ | 5,286 |
| Accrued liabilities | 4,175 | 1,911 | ||
| Deferred revenue | 170 | 170 | ||
| Operating lease liability, current | 226 | 299 | ||
| Notes payable, net of discount (includes note designated at Fair Value Option amounting to $18.1 million as of September 30, 2025, and $11.9 million as of December 31, 2024, respectively) | 23,108 | 12,038 | ||
| Total current liabilities | 36,122 | 19,704 | ||
| Operating lease liability, net of current portion | 918 | 686 | ||
| Deferred revenue, net of current portion | 425 | 553 | ||
| Notes payable, net of discount, net of current portion (includes notes designated at Fair Value Option amounting to $10.7 million as of September 30, 2025, and $21.7 million as of December 31, 2024, respectively) | 7,648 | 23,503 | ||
| Total liabilities | 45,113 | 44,446 | ||
| Commitments and contingencies (See Note 6) | ||||
| Redeemable preferred stock: $0.0001 par value; 179 shares designated from 10,000,000 preferred stock authorized at September 30, 2025, and December 31, 2024; 99 shares issued and outstanding at September 30, 2025 and December 31, 2024 | — | 2,485 | ||
| Stockholders' equity | ||||
| Series G convertible preferred stock: $0.0001 par value; 137 shares designated from 10,000,000 preferred stock authorized at September 30, 2025, and December 31, 2024; zero shares issued and outstanding at September 30, 2025 and December 31, 2024 | — | — | ||
| Series I convertible preferred stock: $0.0001 par value; 118 shares designated from 10,000,000 preferred stock authorized at September 30, 2025, and December 31, 2024; zero shares issued and outstanding at September 30, 2025 and December 31, 2024 | — | — | ||
| Series L perpetual preferred stock: $0.0001 par value; 121 and 0 shares designated from 4,475,074 preferred stock authorized at September 30, 2025, and December 31, 2024, respectively; 121 and 0 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 2,485 | — | ||
| Series M perpetual preferred stock: $0.0001 par value; 260 and 0 shares designated from 4,475,074 preferred stock authorized at September 30, 2025, and December 31, 2024, respectively; 260 and 0 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | — | — | ||
| Series N perpetual preferred stock: $0.0001 par value; 951 and 0 shares designated from 4,475,074 preferred stock authorized at September 30, 2025, and December 31, 2024, respectively; 951 and 0 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | — | — | ||
| Common stock - voting: $0.0001 par value, 298,000,000 shares authorized at September 30, 2025, and December 31, 2024; 3,686,267 and 528,440 issued and outstanding at September 30, 2025, and December 31, 2024, respectively | — | — | ||
| Common stock - non-voting: $0.0001 par value, 50,000,000 shares authorized at September 30, 2025, and December 31, 2024; 9 shares issued and outstanding at September 30, 2025, and December 31, 2024 | — | — | ||
| Additional paid-in capital | 380,836 | 354,234 | ||
| Noncontrolling interest | (1,268) | (791) | ||
| Accumulated deficit | (376,855) | (346,482) | ||
| Accumulated other comprehensive loss | (839) | (467) | ||
| Total stockholders' equity | 4,359 | 6,494 | ||
| Total liabilities, redeemable preferred stock and stockholders' equity | $ | 49,472 | $ | 53,425 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.